Skip to main content

Table 2 Summary of drug-related treatment-emergent adverse events

From: Switching from TNFα inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFα inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial

  Tacrolimus + MTX
(n = 34)
TNFi + MTX
(n = 84)
P-value
TEAE, n (%) 16 (47.1) 19 (22.6) 0.0085
Adverse drug reaction, n (%) 7 (20.6) 6 (7.1) 0.0501
Infections and infestations 1 (2.9) 4 (4.8)  
  Upper respiratory tract infection 0 3 (2.5)  
  Disseminated tuberculosis 1 (2.9) 0  
  Oral herpes simplex infection 0 1 (1.19)  
Gastrointestinal disorders 4 (11.76) 0  
  Abdominal pain 4 (11.76) 0  
Musculoskeletal disorders 1 (2.9) 1 (1.2)  
Lymphatic system disorders 0 1 (1.19)  
  Lymphadenopathy 0 1 (1.19)  
Nervous system disorders 1 (2.94) 0  
  Headache 1 (2.94) 0  
  1. Each value is presented as number (%). MTX, methotrexate; TNFi, tumor necrosis factor inhibitor; TEAE, treatment-emergent adverse event